Acute Graft-Versus-Host Disease

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

SAN DIEGO — Increased fiber intake after allogeneic hematopoietic stem cell transplantation appeared linked to improved outcomes, according to study results presented at ASH Annual Meeting and Exposition.

For years now, transplant physicians have spoken different languages when referring to a matter of utmost relevance — graft-versus-host disease.

A short course of itacitinib induced high response rates among patients with low-risk acute graft-versus-host disease, according to study results.

Antithymocyte globulin decreased incidence of acute graft-versus-host-disease after allogeneic stem cell transplantation from an HLA-matched sibling donor, according to randomized study results published in Journal of Clinical Oncology.

An FDA advisory committee voted 9-1 in favor of approval of the cell therapy remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease.

The FDA granted priority review to the allogeneic cell therapy remestemcel-L for the treatment of children with steroid-refractory acute graft-versus-host disease, according to the agent’s manufacturer.

ORLANDO — Acute graft-versus-host disease tended to be less severe among patients who underwent haploidentical transplantation with post-cyclophosphamide prophylaxis than those who underwent 8/8 HLA-matched unrelated donor stem cell transplant with standard prophylaxis, according to study results presented at TCT | Transplantation & Cellular Therapy Meetings.

ORLANDO — The anti-diabetic medication sitagliptin significantly reduced incidence of acute graft-versus-host disease after myeloablative allogeneic peripheral blood stem cell transplantation, according to results of a prospective phase 2 study presented at TCT | Transplantation & Cellular Therapy Meetings.